

Please type a plus sign (+) inside this box →

+

09-19-02


GP 1653

PTO/SB/21 (6-99)

Approved for use through 09/30/2000. OMB 0651-0031

Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.



# TRANSMITTAL FORM

(to be used for all correspondence after initial filing)

<b>Application Number</b>	09/841,744		
	<b>Filing Date</b>	April 24, 2001	
	<b>First Named Inventor</b>	Jorge F. DiMartino	
	<b>Group/Art Unit</b>	1653	
	<b>Examiner Name</b>	C.M. Kam	
<b>Total Number of Pages in This Submission</b>	13	<b>Attorney Docket Number</b>	12636-891

## ENCLOSURES (check all that apply)

<input type="checkbox"/> Fee Transmittal Form	<input type="checkbox"/> Assignment Papers (for an Application)	<input type="checkbox"/> After Allowance Communication to Group
<input type="checkbox"/> Fee Attached	<input type="checkbox"/> Drawing(s)	<input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences
<input checked="" type="checkbox"/> Amendment / Response	<input type="checkbox"/> Licensing-related Papers	<input type="checkbox"/> Appeal Communication to Group (Appeal Notice, Brief, Reply Brief)
<input type="checkbox"/> After Final	<input type="checkbox"/> Petition Routing Slip (PTO/SB/69) and Accompanying Petition	<input type="checkbox"/> Proprietary Information
<input checked="" type="checkbox"/> Version with Markings Showing Changes	<input type="checkbox"/> Petition to Convert to a Provisional Application	<input type="checkbox"/> Status Letter
<input type="checkbox"/> Affidavits/declaration(s)	<input type="checkbox"/> Power of Attorney, Revocation Change of Correspondence Address	<input type="checkbox"/> Additional Enclosure(s) (please identify below):
<input type="checkbox"/> Extension of Time Request	<input type="checkbox"/> Terminal Disclaimer	<div>RECEIVED SEP 20 2002 TECH CENTER 1600/2300</div>
<input type="checkbox"/> Information Disclosure Statement	<input type="checkbox"/> Small Entity Statement	
<input type="checkbox"/> Certified Copy of Priority Document(s)	<input type="checkbox"/> Request for Refund	
<input type="checkbox"/> Response to Missing Parts/ Incomplete Application	Remarks	
<input type="checkbox"/> Response to Missing Parts under 37 CFR 1.52 or 1.53		

## SIGNATURE OF APPLICANT, ATTORNEY OR AGENT

<b>Firm or Individual name</b>	Shirley Chen, Ph.D., Reg. No. 44,608, WILSON SONSINI GOODRICH & ROSATI		
<b>Signature</b>			
<b>Date</b>	September 17, 2002	<b>Customer Number:</b>	021971

## CERTIFICATE OF EXPRESS MAILING


I hereby certify that this correspondence is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 C.F.R. §1.10 on the date indicated below and addressed to: Commissioner for Patents, Washington, D.C. 20231, on this date: September 17, 2002			
		Express Mail Label EL 778600559 US	
<b>Typed or printed name</b>	Donna Hengst		
<b>Signature</b>		<b>Date</b>	September 17, 2002

Burden Hour Statement: This form is estimated to take 0.2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Washington, DC 20231.

# 6/A  
JM

Attorney Docket No. 12636-891

9/23/02



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

RECEIVED

SEP 20 2002

In re Application )  
)  
Inventor(s): Jorge F. DiMartino )  
)  
Application No.: 09/841,744 )  
)  
Filed: April 24, 2001 )  
)  
Title: COMPOSITIONS AND METHODS FOR )  
REESTABLISHING GENE TRANSCRIPTION )  
THROUGH INHIBITION OF DNA METHYLA- )  
TION AND HISTONE DEACETYLASE )

Art Unit: 1653

TECH CENTER 1600/2900

Examiner: KAM, C. M.

AMENDMENT UNDER 37 C.F.R. §1.111

Assistant Commissioner for Patents  
Washington, D.C. 20231

Sir:

Applicants submit this Amendment in response to the Examiner's Office Action mailed June 17, 2002 (Paper No. 5). Also submitted herewith for the Examiner's review is Exhibit A containing abstracts of two references: Piekarz et al. (2001) Blood 98:2865-2868; and Kitazono et al. (2002) Blood 99:2248-2251.

Reconsideration of the above-referenced application is respectfully requested in view of the following amendments and remarks. Attached hereto is a marked-up version of the changes made to the claims by the current amendment. The attached page is captioned "Version with markings to show changes made."

Please amend the above-referenced application as follows:

In the Specification

Please replace the paragraph beginning at page 7, line 14, with the following rewritten paragraph:

- Cancer vaccines are a group of agents that induce the body's specific immune response to tumors. Most of cancer vaccines under research and development and clinical trials are tumor-associated antigens (TAAs). TAA are structures (i.e. proteins, enzymes or carbohydrates) which

A